Title |
New Insights into Tumor-Infiltrating B Lymphocytes in Breast Cancer: Clinical Impacts and Regulatory Mechanisms
|
---|---|
Published in |
Frontiers in immunology, March 2018
|
DOI | 10.3389/fimmu.2018.00470 |
Pubmed ID | |
Authors |
Meng Shen, Jian Wang, Xiubao Ren |
Abstract |
Currently, tumor-infiltrating B lymphocytes have been recognized as a new hallmark of breast cancer (BC). The function seems to be controversial, either with positive, negative, or no significance in BC's prediction and prognosis. Moreover, B-cell infiltrates regulate tumor process through productions of antibodies and interleukin-10. The interactions with other lymphocytes and programmed death-1/PD-1 ligand axis are also documented. The regulatory mechanisms will eventually be incorporated into diagnostic and therapeutic algorithms, thus give guide to clinical treatment. In this review, we give new insights into clinical impacts and regulatory mechanisms of tumor-infiltrating B cells, which heralds a new era in immuno-oncology in BC treatment. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 25% |
Spain | 1 | 25% |
Unknown | 2 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 152 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 26 | 17% |
Student > Master | 21 | 14% |
Researcher | 16 | 11% |
Student > Doctoral Student | 12 | 8% |
Student > Bachelor | 10 | 7% |
Other | 26 | 17% |
Unknown | 41 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 29 | 19% |
Immunology and Microbiology | 28 | 18% |
Medicine and Dentistry | 23 | 15% |
Agricultural and Biological Sciences | 8 | 5% |
Engineering | 5 | 3% |
Other | 14 | 9% |
Unknown | 45 | 30% |